BRN2 is similarly intriguing based on recent evidence that this neural TF drives neuroendocrine differentiation of tumor cells and thereby promotes enzalutamide resistance through loss of luminal lineage features (Bishop et al., 2017). This evidence concerns the gene TF and neoplasm.